Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of CriPec® Docetaxel in Patients With Solid Tumours

NCT02442531 is registered in ClinicalTrials.gov with Cristal Therapeutics as lead sponsor.

NCT NCT02442531
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02442531 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of CriPec® Docetaxel in Patients With Solid Tumours
Lead sponsor
Cristal Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2015
Completion date
July 31, 2018
Enrollment
33 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, metastatic cancer, solid tumors